Comparing the current results to its competitors, Pelthos Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 0 % year on year. The revenue growth was below Pelthos Therapeutics Inc 's competitors' average revenue growth of 65 %, achieved in the same quarter.
Pelthos Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 13.43 %
Pelthos Therapeutics Inc 's Comment on Competition and Industry Peers
The Company operates in the pharmaceutical industry, which is characterized by rapid technological advancements and a focus on proprietary products. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as compounding facilities, academic institutions, governmental agencies, and public and private research institutions. The Company's product, ZELSUVMI, is the first and only FDA-approved prescription therapy for molluscum contagiosum that can be administered outside a medical setting. Key competitive factors for ZELSUVMI include efficacy, safety, convenience, and pricing. The Company primarily competes with other topical products, natural oils, off-label drugs, natural remedies, cantharidin, and medical procedures such as curettage, cryotherapy, and laser surgery. The Company holds an exclusive license from Ligand to seek approval and commercialize ZELSUVMI globally, excluding Japan.
Black Diamond Therapeutics Inc's business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Inmune Bio Inc is a biotechnology company that focuses on developing innovative therapies for treating cancer and neurodegenerative diseases. Their business model revolves around conducting research and clinical trials to develop novel drug candidates targeting specific proteins involved in immune regulation and inflammation. They aim to license or partner their drug candidates with pharmaceutical companies for further development and commercialization, potentially generating revenue through licensing agreements or royalties.
Ionis Pharmaceuticals Inc is a biopharmaceutical company that operates on a two-fold business model. Firstly, the company focuses on discovering and developing antisense drugs, utilizing a unique RNA-targeted technology. Secondly, Ionis collaborates with established pharmaceutical partners to license and commercialize their drugs, allowing for maximum reach and potential commercial success.
Sources:
Pelthos Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pelthos Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
